VERU vs. XERS, NATR, HOWL, MACK, CDT, TRVI, ELYM, OVID, ZVRA, and GBIO
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Xeris Biopharma (XERS), Nature's Sunshine Products (NATR), Werewolf Therapeutics (HOWL), Merrimack Pharmaceuticals (MACK), Conduit Pharmaceuticals (CDT), Trevi Therapeutics (TRVI), Eliem Therapeutics (ELYM), Ovid Therapeutics (OVID), Zevra Therapeutics (ZVRA), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
In the previous week, Veru had 21 more articles in the media than Xeris Biopharma. MarketBeat recorded 21 mentions for Veru and 0 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.49 beat Veru's score of 0.00 indicating that Veru is being referred to more favorably in the news media.
Xeris Biopharma has higher revenue and earnings than Veru. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a net margin of -37.58% compared to Xeris Biopharma's net margin of -265.27%. Xeris Biopharma's return on equity of -130.13% beat Veru's return on equity.
Xeris Biopharma presently has a consensus target price of $4.63, suggesting a potential upside of 133.59%. Veru has a consensus target price of $4.00, suggesting a potential upside of 203.03%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Veru is more favorable than Xeris Biopharma.
Xeris Biopharma has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Veru has a beta of -0.47, indicating that its stock price is 147% less volatile than the S&P 500.
Veru received 130 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 69.59% of users gave Veru an outperform vote.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Veru beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.
Get Veru News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
